Genprex (NASDAQ:GNPX) Shares Down 1.1% – Time to Sell?

Genprex (NASDAQ:GNPX) shares traded down 1.1% during trading on Monday. The stock traded as low as $2.57 and last traded at $2.69. 275,523 shares changed hands during trading, an increase of 1% from the average session volume of 272,023 shares. The stock had previously closed at $2.72.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Genprex Price Performance

The stock’s 50-day moving average is $3.58 and its 200 day moving average is $12.84. The company has a market cap of $2.21 million, a PE ratio of -0.02 and a beta of -0.99.

Genprex (NASDAQ:GNPX) last announced its earnings results on Friday, August 14th. The company reported ($9.40) earnings per share (EPS) for the quarter.

Institutional Trading of Genprex

A hedge fund recently bought a new position in Genprex stock. Mayflower Financial Advisors LLC bought a new position in shares of Genprex (NASDAQ:GNPX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 20,000 shares of the company’s stock, valued at approximately $36,000. Mayflower Financial Advisors LLC owned 0.22% of Genprex as of its most recent SEC filing. Institutional investors own 14.05% of the company’s stock.

About Genprex

Genprex, Inc is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s lead product candidate is ofranergene obadenovec, also known as REQORSA Therapeutics, an investigational nonviral gene therapy designed to deliver the TUSC2 tumor-suppressor gene to cancer cells.

Genprex has primarily studied REQORSA in combination with other treatments for non-small cell lung cancer, including immune checkpoint inhibitors and targeted therapies.